Prolor reports success in toxicology study

Prolor Biotech Inc. (AMEX: PBTH; TASE: PBTH) today reported positive results from a preclinical toxicology study of its reversible-pegylation technology (RPeg), which found that it was safe and well-tolerated in high doses given to rats.

Prolor uses the RPeg platform to develop long-acting therapeutic peptides and small molecules. It is currently used in the development of its preclinical drug candidate MOD-6030, a peptide for the treatment of obesity and type 2 diabetes. The company expects that RPeg will be especially well suited for use with drugs that must cross the blood-brain barrier.

Prolor president Shai Novik said, "The positive results of this toxicology study are an important milestone as Prolor continues the preclinical development of MOD-6030, which is expected to enter clinical trials next year. These results also add to the positive preclinical safety data supporting the use of RPeg as a safe and well-tolerated platform for the development of a broad range of long-acting peptides and small molecule drugs. We intend to apply RPeg to internal projects and also to share these data with potential partners whose drug candidates may benefit from this promising technology."

Published by Globes [online], Israel business news - www.globes-online.com - on October 16, 2012